Is Pelthos Therapeutics struggling financially?

Yes, by its own account. Pelthos Therapeutics told the SEC on 19 Mar 2026, in Form 10-K, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Mar 2026

30/100

Fragile

Sector: Biotech/Pharma
Market cap: $97.7M
Source filing: 10-K 19 Mar 2026
Balance sheet: 30 Jun 2026

Cash runway

10months

If the burn speeds up

Empty by Apr 2027
15months

If it eases off

Empty by Sep 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$24.2M

Cash burned over the last 12 months

$22.7M

What Pelthos Therapeutics told the SEC

…2024 stated that certain factors, including that we had suffered recurring losses from operations and had an accumulated deficit at December 31, 2024, raised substantial doubt as to our ability to continue as a going concern. Because we were not yet producing sufficient revenue to sustain our operating costs, we were dependent upon raising capital to continue our business. The report of the independent…

Pelthos Therapeutics Inc., Form 10-K, filed 19 Mar 2026.

Read the filing on SEC.gov

What this means

Not a bankruptcy filing, and not a prediction.
It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

446.7% share-count increase The company issued stock. Each share now owns 81.7% less of the business than a year ago, before any change in the price.
Cash burn is increasing It is spending 202% more cash per year than it was, so the runway above shortens even if nothing else changes.

Cash runway

The runway math

What Pelthos Therapeutics told the SEC

What this means

What else the numbers show

Other Biotech/Pharma companies that filed the doubt